TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare first-line erlotinib followed at progression by
second-line chemotherapy vs. first-line chemotherapy followed at progression by second-line
erlotinib in the treatment of Advanced Non Small Cell Lung Cancer (NSCLC).
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute, Naples
Collaborators:
Princess Margaret Hospital, Canada San Giuseppe Moscati Hospital Second University of Naples University of Alberta University of Campania "Luigi Vanvitelli"